Merck & Co: stocks, financial statements

Dividends News
Favorites

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species, which it sells to veterinarians, distributors, and animal producers. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the Company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

  • MRK Ticker
  • NYSE Exchange
  • 69,000 Employees
31 rated
  • $76.61, $-0.62 (-0.80%) Previous Close
  • 19,351,902 Previous Volume
  • $15.19 / $85.00 52 week low / high
  • -9.87% Percent off 52 week high
  • 2021-06-18 Updated
  • 3.29% Dividend Yield (trailing)
  • 3.39% Dividend Yield (forward)
  • 0 Public float
  • 2,532,058,364 Outstanding shares
  • 27.61 P/E
  • 193.98 B Market Cap
Disable ads for free

Financial statements — Merck & Co

The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
20 ← 16 2020 2019 2018 2017 2016
Total Revenue
48B 47B 42B 40B 40B
Cost Of Revenue
15B 14B 14B 13B 14B
Gross Profit
33B 33B 29B 27B 26B
Research and Development
14B 9.9B 9.8B 10B 10B
Selling General and Admin
10B 11B 10B 9.8B 9.8B
Operating Expense
40B 35B 33B 33B 34B
Operating Income
8.5B 12B 8.9B 7.3B 6B
Other Income Expense Net
0 0 0 0 0
EBIT
8.5B 12B 8.9B 7.4B 6.1B
Interest Income
770M 620M 430M 370M 370M
Pretax Income
8.8B 11B 8.7B 6.5B 4.7B
Income Tax
1.7B 1.7B 2.5B 4.1B 720M
Minority Interest
15M -66M -27M 24M 21M
Net Income
7.1B 9.8B 6.2B 2.4B 3.9B
Net Income Basic
7.1B 9.8B 6.2B 2.4B 3.9B
20 ← 16 2020 2019 2018 2017 2016
Current cash
8.1B 10B 8.9B 8.5B 14B
Short term investments
5.5B 4.3B 4.5B 4.3B 4.4B
Receivables
7.9B 6.8B 7.1B 6.9B 7B
Inventory
6.3B 6B 5.4B 5.1B 4.9B
Other current assets
5.5B 4.3B 4.5B 4.3B 4.4B
Current assets
28B 27B 26B 25B 31B
Long term investments
64B 57B 57B 63B 65B
Property plant equipment
18B 15B 13B 12B 12B
Goodwill
20B 19B 18B 18B 18B
Intangible assets
15B 14B 11B 14B 17B
Other assets
10B 6.8B 7.6B 6.1B 5.9B
Total assets
92B 84B 83B 88B 95B
Accounts payable
4.6B 3.7B 3.3B 3.1B 2.8B
Current long term debt
6.4B 3.6B 5.3B 3.1B 570M
Other current liabilities
16B 15B 14B 12B 14B
Total current liabilities
27B 22B 22B 19B 17B
Long term debt
25B 23B 20B 21B 24B
Other liabilities
12B 12B 12B 11B 8.5B
Minority Interest
87M 94M 180M 230M 220M
Total Liabilities
66B 58B 56B 54B 55B
Common stock
2.5B 2.6B 2.7B 2.7B 2.8B
Retained earning
47B 47B 43B 41B 44B
Treasury stock
-57B -56B -51B -44B -41B
Capital surplus
Shareholder equity
25B 26B 27B 34B 40B
Net tangible assets
-9.5B -7.7B -3B 1.9B 4.6B
20 ← 16 2020 2019 2018 2017 2016
Net Income
7.1B 9.8B 6.2B 2.4B 3.9B
Depreciation
3.6B 3.7B 4.5B 4.6B 5.4B
Changes in receivables
1.1B -290M 200M -150M 530M
Changes in inventories
330M 540M 340M 230M 170M
Cash change
-2.4B 1.6B 370M -5.8B 910M
Cash flow
10B 13B 11B 6.4B 10B
Capital expenditures
-4.7B -3.5B -2.6B -1.9B -1.6B
Investments
Investing activity other
Total investing cash flows
-9.4B -2.6B 4.3B 2.7B -3.2B
Dividends paid
Net borrowings
18B 12B 12B 12B 6.1B
Other financing cash flows
Cash flow financing
-2.8B -8.9B -13B -10B -9B
Exchange rate effect